Novartis halts ALS drug development after mid-stage trial fails

Novartis AG (NYSE: NVS) has discontinued development of an experimental drug for amyotrophic lateral sclerosis, commonly known as ALS or Lou Gehrig's disease, after a mid-stage clinical trial failed to demonstrate the treatment worked better than a placebo in slowing disease progression.

The company confirmed the decision in an emailed statement. The discontinued drug, VHB937, is a monoclonal antibody that researchers had hoped would engage the immune system to protect brain cells from damage.

ALS is a fast-progressing neurological condition that causes paralysis, difficulty swallowing, and trouble breathing.

You May Also Be Interested In

• Coca-Cola picks Omnicom for North America, keeps WPP globally
• Rambus invests in ChipAgents, adopts its AI chip design platform
• SpaceX in talks to access 80,000 cell sites for wireless network - Bloomberg